33 results
DEFA14A
AEON
AEON Biopharma Inc. - Ordinary Shares
14 May 24
Additional proxy soliciting materials
9:14am
technology, reputation, customer service and access to technical information.
We are currently focusing our clinical efforts on the use of botulinum … in the form of a REMS;
be sued; or
experience damage to our reputation.
Our product development costs will also increase if we experience delays in testing
8-K
EX-10.13
9cwkm0o77ilnvgmnjl
27 Jul 23
Index to Financial Statements
5:28pm
8-K
EX-14.1
yzgz5drfs6hw5t1
27 Jul 23
Index to Financial Statements
5:28pm
8-K
EX-10.12
b9kz8up3hb4x2 pk
27 Jul 23
Index to Financial Statements
5:28pm
8-K
EX-10.11
ta31dwfh
27 Jul 23
Index to Financial Statements
5:28pm
DEFM14A
i03 gjmb2dm
12 May 23
Proxy related to merger
5:00pm
424B3
bgccsy
12 May 23
Prospectus supplement
4:33pm